Tirzepatide vs Survodutide: Head-to-Head Comparison
Tirzepatide is an FDA-approved dual GIP/GLP-1 agonist with up to 22.5% weight loss. Survodutide is an investigational dual GLP-1/glucagon agonist showing up to 19% weight loss with particular promise for liver fat reduction (MASH). Both are dual agonists but target different receptor combinations.
Side-by-Side Comparison
| Dimension | Tirzepatide | Survodutide |
|---|---|---|
| Evidence Level | Level A — Phase 3 RCTs completed and approved | Level B — Phase 2 data; Phase 3 ongoing (SYNCHRONIZE) |
| FDA Status | Approved for T2D (Mounjaro) and obesity (Zepbound) | Not approved; in Phase 3 trials |
| Weight Loss Efficacy | Up to 22.5% (SURMOUNT-1) | Up to 19% (Phase 2 at 46 weeks) |
| Mechanism | Dual agonist: GIP + GLP-1 receptors | Dual agonist: GLP-1 + glucagon receptors |
| Liver Fat / MASH Benefit | Some liver fat reduction observed | Significant liver fat reduction; MASH trials underway |
| Availability | Available by prescription now | Not yet available; still in clinical trials |
Peptide Overviews
Tirzepatide
AFDA ApprovedTirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.
Survodutide
BHuman StudiesSurvodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. In Phase 3 trials, it demonstrates significant weight loss and is also being investigated for metabolic dysfunction-associated steatohepatitis (MASH/NAFLD).
Tirzepatide vs Survodutide: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.